Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant chemotherapy + immune checkpoint inhibitor + statin in locally advanced gastric and gastroesophageal junction adenocarcinoma
ChiCTR2500110601Phase 2Not yet recruiting
- Sponsor
- Second Hospital of Lanzhou University
- Start
- Oct 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ulinastatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Second Hospital of Lanzhou University. Primary endpoints: Complete response rate and Disease control rate. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
ulinastatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500110601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110601.